GBS another rare complication from COVID-19 vaccines
A Queensland woman has developed Guillain-Barre syndrome (GBS) after her COVID-19 AstraZeneca vaccination, according to a consumer media report.
“We are also monitoring reports of cardiac issues following vaccination with Comirnaty and reports of Guillain-Barre Syndrome following vaccination with the AstraZeneca vaccine, but no causal association with either vaccine has been established at this stage,” a TGA safety report said last month.
The rare condition is known to develop in some patients following infections or vaccinations.
For example, the TGA closely monitored the rate of GBS in the Australian community during the Panvax immunisation program in response to the swine flu pandemic in 2009-2010.
It concluded that there was no evidence of an increased rate of GBS in people receiving Panvax compared with that normally seen in the community.
Sporadic ALS linked to gene mutation
A novel gene called TP73 has been linked to an increased risk of developing sporadic ALS.
Researchers at the University of Utah in Salt Lake City used exome sequencing in more than 2900 people with sporadic AS and found mutations in the gene TP73 in many cases. They also showed that TP73 gene mutations led to abnormal cell differentiation and increased cell death.
They also used CRISPR gene editing technology to remove the TP73 gene and found it led to impaired development of nerve cells, similar to what is seen in ALS.